Vaccine (Adenoviral vector) · Immune activation, directed at HIV Gag · developed by Emergent BioSolutions
Ad4-mgag is a live replication-competent adenovirus type-4 vector vaccine encoding a mosaic HIV Gag antigen, delivered orally via enteric-coated capsules to elicit immune responses against HIV.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02771730 | Phase 1 | Healthy Volunteer | Terminated | EBS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy VolunteerHIV Vaccine
Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.
See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EBS catalysts and pipeline →